Health Condition 1: L700- Acne vulgaris
Conditions
Interventions
Intervention1: Nixoderm tube: Product to be applied twice a day at the site of acnes & blemishes Duration 30 days
Dosage form: Cream (Topical application)
Control Intervention1: Placebo: Product to be
Sponsors
M/s.SC Johnson & Son Nigeria Ltd
Eligibility
Inclusion criteria
Inclusion criteria: Aged between 18-65 years 2. Both male and female 3. Participants diagnosed with acne vulgaris on face with mild to moderate severity 4. Willing to give Informed Consent. 5. Willing to complete the study assessments/questionnaires. 6. Willing to avoid usage of his/her own skin care products for at least one week before the commencement and during this study.
Exclusion criteria
Exclusion criteria: 1. Pregnancy or breast feeding. 2. Participants with history of hypersensitivity to skin care products. 3. Participants with mild to severe anaphylaxis reaction. 4. Participants with pre-existing severe systemic disease necessitating long term medication. 5. Participants with any other concomitant skin diseases such as psoriasis, eczema etc. 6. Evidence of significant uncontrolled co-morbid disease which in the investigators opinion would jeopardize patient participation. 7. History of cancer, including solid tumors, hematologic malignancies and carcinoma in situ. 8. Participation in the current or previous clinical trial with any approved or investigational products during the past 1 month.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Sebumeter Global Acne Grading System (GAGS) Assessment of Acne Quality of Life Index (Acne-QOLI)Timepoint: Day 0,Day 7,Day 15 and Day 30 | — |
Secondary
| Measure | Time frame |
|---|---|
| Dermatological AssessmentsTimepoint: Day 7,Day 15 and Day 30 | — |
Countries
India
Contacts
Public ContactDr Ashok Godavarthi
Radiant Research services Pvt Ltd
Outcome results
None listed